Physician profile
Andrew E Coles
NPI 1982721106
$1,074.53
in general payments reported to CMS, 2019-2025
25 companies · $43.16 in 2025
The $43.16 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $95.01 · 2021: $278 · 2022: $167 · 2023: $193 · 2024: $78.86 · 2025: $43.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $210.70 | 2019-2024 | Xtampza |
| Amgen INC. | $134.60 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $110.54 | 2019-2021 | |
| Lundbeck LLC | $102.37 | 2022-2024 | Vyepti |
| Abbvie INC. | $71.86 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.69 | 2019-2024 | Relistor |
| Lilly USA, LLC | $42.19 | 2020-2021 | |
| Horizon Therapeutics Plc | $31.65 | 2022-2023 | Krystexxa |
| Pfizer INC. | $31.06 | 2019-2023 | |
| Boston Scientific Corporation | $29.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.68 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $26.35 | 2023 | Horizant |
| Merz Pharmaceuticals, LLC | $19.46 | 2024 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $18.62 | 2025 | |
| Mdd US Operations, LLC | $16.71 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $14.46 | 2022 | |
| Averitas Pharma INC. | $14.40 | 2024 | Qutenza |
| Grt US Holding, INC. | $14.31 | 2021 | |
| Allergan, INC. | $13.88 | 2020 | |
| Shionogi INC | $13.14 | 2019 | |
| Kaleo, INC. | $12.79 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.28 | 2021 | |
| Virtus Pharmaceuticals LLC | $11.85 | 2021 | |
| Redhill Biopharma INC. | $11.72 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Coles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.